Navigation Links
Macrocyclics presenta nuevos productos
Date:1/10/2014

DALLAS, 10 de enero de 2014 /PRNewswire/ -- Macrocyclics, Inc. (compañía de AREVA Med) anunció hoy la presentación de cuatro nuevos productos que ampliarán las aplicaciones de imágenes PET con cobre-64 y galio-68 usando plataformas quelatantes basadas en NOTA. Además, un nuevo conjugado de DOTA basado en serotonina ofrece el potencial para obtener imágenes de neurotransmisión serotoninérgicas utilizando un radioisótopo o con gadolinio mediante imágenes por resonancia magnética (MRI).

(Logo: http://photos.prnewswire.com/prnh/20130523/DA20136LOGO)

Visite www.macrocyclics.com para obtener más información.

MÁS ACERCA DE MACROCYCLICS
Macrocyclics es el líder global en tecnologías de agentes quelatantes de alto desempeño para la medicina desde 1995. El equipo de Macrocyclics se dedica a proveer a los clientes agentes quelatantes y servicios tanto establecidos como innovadores para superar los desafíos de las imágenes moleculares y la medicina nuclear. www.macrocyclics.com

MÁS ACERCA DE AREVA MED
AREVA Med es una subsidiaria de AREVA que se especializa en el desarrollo de tratamientos innovadores para luchar contra el cáncer. AREVA Med creó nuevos procesos para producir plomo-212 (²¹²Pb) de alta pureza, un metal poco común que actualmente se encuentra en el centro de prometedoras investigaciones de medicina nuclear. En 2011, AREVA Med adquirió Macrocyclics, líder global en tecnología de agentes quelatantes de alto desempeño. AREVA Med también formó alianzas con socios científicos de primer nivel, como el Instituto Nacional del Cáncer (National Cancer Institute, NCI), la Universidad de Alabama en Birmingham (University of Alabama at Birmingham, UAB) y el Instituto Nacional Francés de Salud e Investigación Médica (French National Institute of Health and Medical Research, Inserm). En 2012, AREVA Med y Roche formaron una alianza estratégica para crear nuevos tratamientos avanzados de radioinmunoterapia alfa para atacar y matar ciertos tipos de células cancerígenas muy agresivas. Para obtener más información: http://arevamed.areva.com/ o www.targetedtrials.com.

Macrocyclics
Garry Kiefer
Teléfono: +1 972 250 2248
Fax: +1 972 250 2245
info@macrocyclics.com

AREVA Med
Alison Tise
Teléfono: +1 301 841 1673
Fax: +1 434 382 4250
alison.tise@areva.com

FUENTE  Macrocyclics, Inc.

FUENTE Macrocyclics, Inc.


'/>"/>
SOURCE Macrocyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Macrocyclics apresenta novos produtos
2. Macrocyclics introduces new products
3. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
4. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
5. Cepheid to Webcast Upcoming Financial Presentation
6. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
7. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
8. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
9. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Nora Therapeutics Announces New Time for Presentation at the Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... DUBAI , VAE, January 20, 2017 ... den stark gestiegenen Bedarf an Nothilfe   Die ... um Platz für Hilfsgüter zu schaffen   ... Vizepräsident und Premierminister der VAE sowie Herrscher von ... Umfang der internationalen Stadt der Hilfe (International Humanitarian City ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... Devices Market? Which areas are going to grow at ... revenues to 2026, assessing data, trends, opportunities and prospects. ... graphs. Discover the most lucrative areas in the industry ... you assess forecasted sales across the all the major ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... for Leading Companies – our new study reveals trends, ... issues and events affecting the Alzheimer,s disease therapeutics and ... answer these key questions: - How is the Alzheimer,s ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel Biocare™ dental implant ... media for its creos™ line of bone regenerative products. Specifically, the ... he utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. ...
(Date:1/20/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has posted a ... Yisrayl says this generation is a time like no other and society needs to understand ... Yisrayl says he does not want to sound like an old bible beater because religion ...
(Date:1/20/2017)... ... ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality nutritional ... ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures its ... products to all clients at reasonable prices. At the ECRM trade show, it had ...
(Date:1/20/2017)... ... ... International Protein, a company based out of Australia that focuses on developing ... trade show in Hilton Head, SC. , International Protein was founded by Christine ... of products that would elevate her fitness regime. At this ECRM trade show, Envall ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... sugar-free alternative VW+ 002. The drinks have been produced in collaboration with Zlatan ... perform during your workout. , After a successful launch in Sweden last year, ...
Breaking Medicine News(10 mins):